That big new hy­per­parathy­roidism drug from Am­gen? The FDA re­ject­ed it

Ac­cord­ing to reg­u­lar up­dates from Am­gen over the past two years, in­ves­ti­ga­tors marched through a trio of late-stage stud­ies for etel­cal­ce­tide (AMG416) with noth­ing but good things to re­port. The drug scored out­stand­ing da­ta for sec­ondary hy­per­parathy­roidism (SH­PT), a dis­ease that af­fects chron­ic kid­ney dis­ease pa­tients on he­modi­a­lyis.

And this evening Am­gen re­port­ed that the drug was re­ject­ed by the FDA. The news came in a terse state­ment, with­out a hint about what the agency ob­ject­ed to.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER